FDA Approval

Cardio3 BioSciences Receives IND Clearance from the FDA for its CHART-2 Phase III Heart Failure Clinical Trial

Cardio3 BioSciences Receives IND Clearance from the FDA for its CHART-2 Phase III Heart Failure Clinical Trial PR Newswire MONT-SAINT-GUIBERT, Belgium, January 9, 2014 MONT-SAINT-GUIBERT, Belgium , January 9, 2014 /PRNewswire/ — Cardio3 BioSciences (C3BS) ( NYSE Euronext Brussels and Paris : CARD ), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, announces today that the U.S. Food and Drug Administration (FDA) has authorized the Company’s Investigational New Drug (IND) application for clinical testing of the Company’s proprietary regenerative medicine product C3BS-CQR-1 (C-Cure) as a treatment targeting heart failure. CHART-2, the Company’s second Phase III clinical trial, is intended to assess in the US, the efficacy of C3BS-CQR-1 as a treatment for heart failure of ischemic origin […]

Mergers & Acquisitions

Scientific Games Sells Stake in Sportech PLC

Scientific Games Sells Stake in Sportech PLC PR Newswire NEW YORK, Jan. 9, 2014 NEW YORK , Jan. 9, 2014 /PRNewswire/ — Scientific Games Corporation (Nasdaq: SGMS) (the “Company”) today announced the sale of 39,742,179 shares of Sportech PLC (LSE: SPO) (“Sportech”) for gross cash proceeds of GBP 27.8 million […]

Stock Analysts

Affymetrix Up on Upbeat Rev Guidance

Affymetrix Inc. ( AFFX ) announced its preliminary revenue guidance for the fourth quarter and full year 2013. Affymetrix’ shares gained over 11.5% on Jan 7 to end the day’s trading at $8.81 on the back of the optimistic guidance. […]